RR

Active Director Director DIN 08287247
DIN 08287247 First appointment Nov 2018 Primary industry Food And Beverages
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2018
Shareholding value •••• Premium profile

About Rahul Rai

Data last updated:

Rahul Rai is a Director at Rejonent Pharmaceuticals Private Limited (since 2018). The company operates in Food And Beverages. Rejonent Pharmaceuticals Private Limited reported revenue of ₹9.2 Lakh (FY 2025).

DIN 08287247
Primary Designation Director
Industry Food And Beverages
First Appointment 26 Nov 2018
Oldest Company Age 7 yrs
Largest company Rejonent Pharmaceuticals Private Limited · ₹9.2 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director26 Nov 20182018₹9.2 Lakh (FY 2025)Active

Board colleagues of Rahul Rai

NameDINCompanyDesignation
Neeraj Rai08287248Rejonent Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Rejonent Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Rahul Rai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rahul Rai

Rahul Rai currently holds 1 directorship: Rejonent Pharmaceuticals Private Limited (Director, since 26 Nov 2018, revenue ₹9.2 Lakh (FY 2025)).

Rahul Rai was first appointed on 26 Nov 2018 as Director at Rejonent Pharmaceuticals Private Limited.

The current boards of Rahul Rai's companies include Neeraj Rai (Rejonent Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available